These findings indicate that mangiferin ameliorates NAFLD by modulating glycolipid metabolism through AMPK activation and inhibiting NLRP3-mediated inflammation. This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatotic liver disease.